-
Real-World Evidence on Clinical Outcomes and Safety of Trastuzumab Biosimilar in Colombian Breast Cancer Patients
Mar 10, 2025, 14:00 PM -
The Relationship Between Weight and Disease Severity in Dogs with Chronic Kidney Disease: Results from a Real-World Study
Mar 10, 2025, 14:00 PM -
A Conceptual Epidemiological and Economic Model to Predict Obesity in Low- and Middle-Income Countries: A Meta-Synthesis
Mar 10, 2025, 14:00 PM -
Prenatal Exposure to Antiseizure Medication and Risk of Adverse Obstetrical Outcomes: A Population-Based Study
Mar 10, 2025, 14:00 PM -
Advancing Health Equity in Economic Evaluations, With The Distributional Generalized Risk-Adjusted Cost-Effectiveness (DGRACE) Model
Mar 10, 2025, 14:00 PM -
Treatment Experience and Other Health and Social Characteristics Among Patients With Cancer From a Large US Population-Based Survey
Mar 10, 2025, 14:00 PM -
Evaluating Attributes of Non-Oncology Orphan Approvals From 2015-2024
Mar 10, 2025, 14:00 PM -
JAV-RARAS: Analysis of Adherence to Clinical Protocols and Therapeutic Guidelines (PCDT) for Rare Diseases – A Comparison of Real-World Clinical Practice in the Context of the Value-Based Care Journey for RARAS.
Mar 10, 2025, 14:00 PM -
Evidence for the Cumulative Impact of Social Determinants of Health (SDOH) on Cancer Mortality: A Scoping Review
Mar 10, 2025, 14:00 PM -
Why It Is Still Important to Ensure the Price is Right: Updates to Access Restrictions for Therapies Treating Duchenne Muscular Dystrophy
Mar 10, 2025, 14:00 PM -
Using Machine Learning to Estimate Perceptions and Future Prescribing Intentions of Health Care Providers: A Novel Application of Integrated Primary and Secondary Data in Understanding HCP Decision-Making
Mar 10, 2025, 14:00 PM -
Optimized Treatment Sequences for ALK+ Stage IV NSCLC: Cost-Effectiveness Analysis From RCT data and Real-World Evidence
Mar 10, 2025, 14:00 PM -
Cost-Effectiveness Analysis of Axicabtagene Ciloleucel as a Second-Line Treatment for Diffuse Large B-Cell Lymphoma in China
Mar 10, 2025, 14:00 PM -
A Cost Per Responder Analysis of Ritlecitinib and Baricitinib: Assessing the Impact of Clinical Efficacy and Dosing Variability on Overall Treatment Costs of Severe Alopecia Areata (AA)
Mar 10, 2025, 14:00 PM -
Evaluation of Marginal Healthcare Expenditures and Health-related Quality of Life in Multiple Sclerosis with a Bayesian Quantile Machine Learning Approach
Mar 10, 2025, 14:00 PM -
How Disease Modifying Therapy Utilization In Multiple Sclerosis Is Influenced by Insurance and Out-Of-Pocket Cost in US Adults: A Summary Of Recent Literature
Mar 10, 2025, 14:00 PM -
The Use of QALYs in Decision-Making in Europe, Canada, and the US: A Qualitative Review of Methodological Guidance
Mar 10, 2025, 14:00 PM -
Cost-Effectiveness of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection in HER2-Positive Early Breast Cancer in China: A Post-Hoc Analysis of the FeDeriCa Trial
Mar 10, 2025, 14:00 PM -
Psychometric Validation of the Sunlight Exposure Diary and Erythropoietic Protoporphyria Impact Questionnaire (EPIQ) Using Data from the AURORA Clinical Study in Erythropoietic Protoporphyria (EPP)
Mar 10, 2025, 14:00 PM -
Weight Loss Program ( WLP): Clinical and Economic Impact Analysis (CEIA) Preliminary Data From an MCDA Related to the Adherence of Obese Patients' Study in BraziL/LATAM/LMIC
Mar 10, 2025, 14:00 PM
